{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:51:55Z","timestamp":1792180315464,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002570","name":"American Association of Immunologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010637","name":"Huntsman Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010638","name":"Huntsman Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41375-022-01585-2","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T01:22:28Z","timestamp":1651281748000},"page":"1943-1946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion"],"prefix":"10.1038","volume":"36","author":[{"given":"Michael L.","family":"Olson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica R. Vander","family":"Mause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabarinath V.","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-6730","authenticated-orcid":false,"given":"Joshua D.","family":"Brody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana L.","family":"Welm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje","family":"Atanackovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7085-9027","authenticated-orcid":false,"given":"Tim","family":"Luetkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"key":"1585_CR1","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1038\/s41375-020-0831-z","volume":"34","author":"J Pan","year":"2020","unstructured":"Pan J, Tan Y, Deng B, Tong C, Hua L, Ling Z, et al. Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r\/r B-ALL children. Leukemia. 2020;34:3382\u20137.","journal-title":"Leukemia"},{"key":"1585_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1182\/blood.2020009515","volume":"138","author":"K Wudhikarn","year":"2021","unstructured":"Wudhikarn K, Flynn JR, Riviere I, Gonen M, Wang X, Senechal B, et al. Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood. 2021;138:531\u201343.","journal-title":"Blood"},{"key":"1585_CR3","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"key":"1585_CR4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1126\/science.286.5441.952","volume":"286","author":"JF Huang","year":"1999","unstructured":"Huang JF, Yang Y, Sepulveda H, Shi W, Hwang I, Peterson PA, et al. TCR-Mediated Internalization of Peptide-MHC Complexes Acquired by T Cells. Science. 1999;286:952\u20134.","journal-title":"Science"},{"key":"1585_CR5","doi-asserted-by":"publisher","first-page":"17608","DOI":"10.1073\/pnas.1912252116","volume":"116","author":"A Dance","year":"2019","unstructured":"Dance A. Core concept: cells nibble one another via the under-appreciated process of trogocytosis. Proc Natl Acad Sci USA. 2019;116:17608\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1585_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568:112\u20136.","journal-title":"Nature"},{"key":"1585_CR7","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.celrep.2014.06.052","volume":"8","author":"B Chung","year":"2014","unstructured":"Chung B, Stuge TB, Murad JP, Beilhack G, Andersen E, Armstrong BD, et al. Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis. Cell Rep. 2014;8:871\u201382.","journal-title":"Cell Rep"},{"key":"1585_CR8","doi-asserted-by":"publisher","first-page":"7647","DOI":"10.4049\/jimmunol.173.12.7647","volume":"173","author":"M Chmielewski","year":"2004","unstructured":"Chmielewski M, Hombach A, Heuser C, Adams GP, Abken HT. Cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004;173:7647.","journal-title":"J Immunol"},{"key":"1585_CR9","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25:1408\u201314.","journal-title":"Nat Med"},{"key":"1585_CR10","doi-asserted-by":"crossref","unstructured":"Roddie C, Dias J, O\u2019Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, et al. Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. J Clin Oncol. 2021;39:3352\u201363.","DOI":"10.1200\/JCO.21.00917"},{"key":"1585_CR11","unstructured":"Vander Mause ER, Baker JM, Radhakrishnan SV, Davis P, Panse J, Marvin JE, et al. Fast off-rate CD229 chimeric antigen receptor T cells efficiently target multiple myeloma, spare T cells, and exhibit reduced trogocytosis. bioRxiv. 2021: 2021.2012.2006.471279."},{"issue":"Dec","key":"1585_CR12","doi-asserted-by":"publisher","first-page":"6545","DOI":"10.4049\/jimmunol.1001867","volume":"185","author":"S Caserta","year":"2010","unstructured":"Caserta S, Kleczkowska J, Mondino A, Zamoyska R. Reduced functional avidity promotes central and effector memory CD4 T cell responses to tumor-associated antigens. J Immunol. 2010;185(Dec):6545\u201354.","journal-title":"J Immunol"},{"key":"1585_CR13","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.4049\/jimmunol.180.3.1309","volume":"180","author":"NS Joshi","year":"2008","unstructured":"Joshi NS, Kaech SM. Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation. J Immunol. 2008;180:1309\u201315.","journal-title":"J Immunol"},{"key":"1585_CR14","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.ymthe.2017.04.017","volume":"25","author":"S Arcangeli","year":"2017","unstructured":"Arcangeli S, Rotiroti MC, Bardelli M, Simonelli L, Magnani CF, Biondi A, et al. Balance of Anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia. Mol Ther. 2017;25:1933\u201345. 2017\/08\/02\/","journal-title":"Mol Ther"},{"key":"1585_CR15","doi-asserted-by":"publisher","first-page":"1688616","DOI":"10.1080\/19420862.2019.1688616","volume":"12","author":"AP Singh","year":"2020","unstructured":"Singh AP, Zheng X, Lin-Schmidt X, Chen W, Carpenter TJ, Zong A, et al. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. MAbs. 2020;12:1688616.","journal-title":"MAbs"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01585-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01585-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01585-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T03:23:05Z","timestamp":1656904985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01585-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1585"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01585-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.05.471117","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,30]]},"assertion":[{"value":"19 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SVR, DA, and TL are inventors on PCT application US2017\/42840 \u201cAntibodies and CAR T Cells for the Treatment of Multiple Myeloma\u201d describing the therapeutic use of CD229 CAR T cells for the treatment of multiple myeloma. ERV, DA, and TL are inventors on provisional patent application 63\/285843 describing low-affinity CD229 antibodies and CAR T cells. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}